Holen Sie sich die Stockscreener-App
4.58
6.02%
0.26
Schlusskurs vom Vortag:
$4.32
Offen:
$4.34
24-Stunden-Volumen:
331.92K
Relative Volume:
0.62
Marktkapitalisierung:
$166.56M
Einnahmen:
$425.17M
Nettoeinkommen (Verlust:
$-92.21M
KGV:
458.00
EPS:
0.01
Netto-Cashflow:
$-67.42M
1W Leistung:
+8.27%
1M Leistung:
+0.00%
6M Leistung:
-51.22%
1J Leistung:
-72.26%
1-Tages-Spanne:
$4.34
$4.61
1-Wochen-Bereich:
$4.20
$4.82
52-Wochen-Spanne:
$3.95
$22.64
Nevro Corp Stock (NVRO) Company Profile
Firmenname
Nevro Corp
Sektor
Branche
Telefon
650-251-0005
Adresse
1800 BRIDGE PARKWAY, REDWOOD CITY, CA
Vergleichen Sie NVRO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVRO
Nevro Corp
|
4.58 | 166.56M | 425.17M | -92.21M | -67.42M | 0.01 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Nevro Corp Stock (NVRO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-09 | Hochstufung | Citigroup | Sell → Neutral |
| 2024-08-08 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2024-08-07 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-08-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-05-22 | Herabstufung | Citigroup | Neutral → Sell |
| 2024-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-12-21 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-05-31 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-15 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2023-01-17 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-01-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-12-20 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2022-12-12 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Underperform |
| 2022-05-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-04-13 | Fortgesetzt | Truist | Hold |
| 2022-04-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Underperform |
| 2022-01-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2021-11-09 | Herabstufung | Truist | Buy → Hold |
| 2021-08-05 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-05 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-05 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-07-09 | Herabstufung | Redburn | Buy → Neutral |
| 2021-07-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2021-02-02 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-23 | Eingeleitet | Guggenheim | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-08 | Hochstufung | UBS | Sell → Neutral |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-26 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2020-01-06 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-11-07 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-10-22 | Eingeleitet | Oppenheimer | Perform |
| 2019-03-20 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-03-20 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-28 | Eingeleitet | UBS | Sell |
| 2018-11-07 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-10-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-07-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-05-08 | Bestätigt | Canaccord Genuity | Buy |
| 2018-05-08 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-08 | Herabstufung | Wells Fargo | Outperform → Market Perform |
Alle ansehen
Nevro Corp Aktie (NVRO) Neueste Nachrichten
Nevro Corp. (NYSE:NVRO) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Nevro Stock Rises on Q3 Earnings Beat, Revenues Decrease Y/Y - MSN
Nevro’s HFX iQ™ Spinal Cord Technology Receives CE Mark Certification in Europe - TechRound
NVRO Stock Declines Despite Positive Study Data of Nevro1 System - MSN
Nevro Stock May Gain on the CE Mark Certification for HFX iQ - MSN
Nevro secures CE mark for AI-based spinal cord stimulation system - MSN
Nevro’s SI joint fixation system delivers enhanced stability and fusion for patients - Mass Device
Nevro announces publication of new data on Nevro1 SI Joint Fusion System - TipRanks
New Study Demonstrates Multiple Advantages of Nevro1™ | Trending From Our Network - Chicago Star Media
Nevro Corp announces inducement grants - Medical Buyer
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08 - Quantisnow
Engaged Capital LLC Adjusts Its Stake in Nevro Corp - GuruFocus.com
ARMISTICE CAPITAL, LLC Acquires Additional Shares in Nevro Corp - GuruFocus.com
Amendment: SEC Form SC 13D/A filed by Nevro Corp. - Quantisnow
Nevro Corp. Reports Strong Q3 2024 Financial Performance - TipRanks
Nevro Corp. (NVRO) Quarterly 10-Q Report - Quartzy
NVRO stock touches 52-week low at $4.35 amid market challenges - Investing.com
FY2024 Earnings Forecast for Nevro Issued By William Blair - MarketBeat
Nevro Corp.'s SWOT analysis: stock faces headwinds amid market challenges - Investing.com Australia
Analysts Are Updating Their Nevro Corp. (NYSE:NVRO) Estimates After Its Third-Quarter Results - Yahoo Finance
Nevro wins CE mark for spinal cord stimulation technology - BioWorld Online
FY2026 Earnings Estimate for Nevro Issued By William Blair - MarketBeat
Nevro stock price target cut, retains hold rating on earnings release - Investing.com Canada
Nevro Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Nevro Corp’s Market Cap Challenges: Impairment Risks and Investor Concerns - TipRanks
Nevro Corp stock target cut, keeps underweight rating on Q3 results - Investing.com
Nevro wins CE mark for HFX iQ spinal cord stim for pain relief - Mass Device
Nevro price target raised to $6 from $5 at Baird - TipRanks
Nevro stock price target cut, retains underweight on earnings beat - Investing.com
Why Medical Device Firm Nevro Stock Is Trading Higher On TuesdayNevro (NYSE:NVRO) - Benzinga
Nevro (NYSE:NVRO) Price Target Cut to $7.00 by Analysts at Canaccord Genuity Group - MarketBeat
Nevro's (NVRO) "Sector Perform" Rating Reiterated at Royal Bank of Canada - MarketBeat
Peeling Back The Layers: Exploring Nevro Through Analyst Insights - Benzinga
Piper Sandler Cuts Nevro (NYSE:NVRO) Price Target to $6.00 - MarketBeat
Nevro Corp. (NYSE:NVRO) Q3 2024 Earnings Call Transcript - MSN
Nevro (NYSE:NVRO) Price Target Raised to $6.00 - MarketBeat
Nevro Corp stock target upgraded, neutral rating on margin outlook By Investing.com - Investing.com UK
Nevro Corp (NVRO) PT Lowered to $6 at Piper Sandler - StreetInsider.com
Nevro receives CE Mark Certification in Europe for HFX iQ SCS System - TipRanks
Nevro Corp (NVRO) PT Raised to $6 at Baird - StreetInsider.com
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally - PR Newswire
Nevro Corp (NVRO) PT Lowered to $7 at Canaccord Genuity - StreetInsider.com
Nevro price target lowered to $6 from $7 at Piper Sandler - TipRanks
Nevro Corp earnings beat by $0.40, revenue topped estimates - Investing.com Canada
Nevro stock price target cut, retains underweight on earnings beat By Investing.com - Investing.com UK
Nevro Corp. Shows Resilience Amidst Revenue Challenges - TipRanks
Nevro: Q3 Earnings Snapshot - CT Insider
Nevro Corp. Reports Earnings Results for the Third Quarter Ended September 30, 2024 - Marketscreener.com
Finanzdaten der Nevro Corp-Aktie (NVRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):